PerioCell: Immune cell recruitment to treat gum disease

Steven Little, PhD Bioengineering PI
Chair, Department of Chemical and Petroleum Engineering
Associate Professor and CNG Faculty Fellow
Departments of Chemical and Petroleum Engineering, Bioengineering, Immunology and the McGowan Institute for Regenerative Medicine

Charles Sfeir, PhD Clinical PI
Associate Professor of Oral Biology
Director, Center for Craniofacial Regeneration
School of Dental Medicine

Periodontal disease (gum disease) affects an estimated 78 million Americans, and is the leading cause of tooth loss according the American Dental Academy. Current treatments focus on the removal on invasive bacterial species (through scaling and root planing, and antibiotics), although tissue destruction is carried out by the patient's inflammatory immune response. CCl22 controlled release microparticles use the body's own sophisticated immune regulatory mechanisms to address aberrant inflammation and restore tissue homeostasis. Further, this project has already proved efficacy and therapeutic mechanism of the microparticles both in a mouse model, and the most widely accepted preclinical dog model for periodontal disease.